NASDAQ:AVXL

Anavex Life Sciences Q4 2026 Earnings Date & Estimates

Anavex Life Sciences logo
$0.60 -0.07 (-10.86%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$0.61 +0.02 (+3.19%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Anavex Life Sciences is estimated to report Q4 2026 earnings on Tuesday, November 24, 2026, before market opens.

Upcoming Earnings Announcement

Quarter
Q4 2026
Announcement Date
Time
Before Market Opens

What Analysts Expect from Anavex Life Sciences in Q4 2026

Anavex Life Sciences is expected to post earnings of -$0.11 per share. In the same quarter a year earlier Anavex Life Sciences reported -$0.11 per share. Anavex Life Sciences last reported on August 25, 2026, posting $0.08 per share and beating the -$0.08 consensus estimate. Anavex Life Sciences has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.11
Prior-Year EPS
-$0.11

Recent Track Record

Last Reported
Q3 2026
Last Quarter EPS
$0.08 (Beat by +$0.16)
EPS Beat Rate
7 of last 8 quarters

Anavex Life Sciences Q4 2026 Earnings FAQ

Anavex Life Sciences (NASDAQ:AVXL) is estimated to report Q4 2026 earnings on Tuesday, November 24, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Anavex Life Sciences' Q4 2026 earnings conference call is scheduled for Friday, December 11, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Anavex Life Sciences to post earnings of -$0.11 per share for Q4 2026.

Anavex Life Sciences Earnings Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
Anavex Life Sciences Corp. (AVXL)
See More Anavex Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anavex Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anavex Life Sciences and other key companies, straight to your email.

About Anavex Life Sciences

Anavex Life Sciences (NASDAQ:AVXL) is a clinical-stage biopharmaceutical company that researches and develops treatments for neurological and neurodevelopmental disorders. Its work focuses on investigational medicines intended to affect biological pathways involved in the central nervous system.

The company’s lead candidate, blarcamesine (ANAVEX2-73), is an oral investigational drug studied for conditions including Alzheimer’s disease and Rett syndrome. Anavex has also evaluated other drug candidates for neurological disorders. These medicines remain investigational and are not approved treatments.

Founded in 2004, Anavex has conducted clinical studies in multiple countries, including the United States, Australia and countries in Europe. Its research has focused in part on sigma-1 receptor biology, which the company investigates as a potential approach to treating diseases of the central nervous system.

View Anavex Life Sciences Profile